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Deployment of Artificial Intelligence in Real-World Practice:
Opportunity and Challenge
Mingguang He, MD, PhDy, Zhixi Li, MD, PhD, Chi Liu, MSz
Danli Shi, MD, and Zachary Tan, MBBS§{
Abstract: Artificial intelligence has rapidly evolved from the experimental
phase to the implementation phase in many image-driven clinical disciplines,
including ophthalmology. A combination of the increasing availability of
large datasets and computing power with revolutionary progress in deep
learning has created unprecedented opportunities for major breakthrough
improvements in the performance and accuracy of automated diagnoses that
primarily focus on image recognition and feature detection. Such an auto-
mated disease classification would significantly improve the accessibility,
efficiency, and cost-effectiveness of eye care systems where it is less
dependent on human input, potentially enabling diagnosis to be cheaper,
quicker, and more consistent. Although this technology will have a profound
impact on clinical flow and practice patterns sooner or later, translating such a
technology into clinical practice is challenging and requires similar levels of
accountability and effectiveness as any new medication or medical device due
to the potential problems of bias, and ethical, medical, and legal issues that
might arise.The objective of this review is to summarize the opportunities and
challenges of this transition and to facilitate the integration of artificial
intelligence (AI) into routine clinical practice based on our best understanding
and experience in this area.
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ARTIFICIAL INTELLIGENCE, MACHINE LEARNING,
AND DEEP LEARNING
A rtificial intelligence (AI) was first proposed in print in aDartmouth Summer Research Project in 1955.1 AI is a broad
term referring to a branch of computer science that is hypotheti-
cally committed to developing computer algorithms for the tasks
that have traditionally been accomplished by human intelligence,
such as the ability to learn and solve problems. Machine learning
(ML) is a division of AI that provides knowledge in the form of
data to computers, along with observations to optimize the
goodness of fit between input—including text, image, or video
data—and output as a classification. A conceptual and engineer-
ing breakthrough by pioneers of the field, Yoshua Bengio,
Geoffrey Hinton, and Yann LeCun enabled the development of
artificial neural networks and deep learning (DL) to become a
subfield of ML. This technology requires multiple processing
layers to learn and detect features ranging from simple ones such
as lines, edges, textures, and intensity, to complex features like
shapes, lesions, and a whole image in a hierarchical structure.
Neural networks, inspired by simulating the neurons in the
brain, include algorithms that are commonly used for image
analysis today. These neural networks are composed of a number
of layers of connected nodes, where each node receives informa-
tion from other nodes and also sends a signal to other groups of
nodes. The goal of the overall network is to find an answer that
matches a defined ground-truth label by changing the pattern and
weights of node connections via thousands of millions of attempts
until the best match of the ground truth is achieved. Many types of
neural structures have been proposed, representing various ways
to cluster those nodes. The most common type of neural network
used for image recognition is a convolutional neural network
(CNN).2
The “training” of neural networks is conducted either by
supervised learning, where a training set of data with annotations
by humans to match the disease outcome are used, or unsuper-
vised learning, in which the training data do not have annotations
and where the algorithm strives to cluster or organize to
“understand” the underlying patterns. The majority of ML sys-
tems to date in ophthalmology are developed using supervised
learning,2,3 wherein the CNN analyzes pixel data from a large
number of manually labeled images to determine a specific
classification of disease type and severity.
CURRENT STATUS OF AI DEVELOPMENT IN
OPHTHALMOLOGY
Ophthalmology is a branch of medicine that deals with the
diagnosis and treatment of eye diseases. A number of imaging
modalities have been used for the diagnosis of eye diseases;
however, the interpretation of these images is highly dependent
on the skill and experience of physicians, and this process is often
subjective, with substantial interobserver variation.4–6 Evidence
supporting this includes a study wherein even senior glaucoma
specialists could only achieve a “substantial” level of agreement
From the State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic
Center, Sun Yat-sen University, Guangzhou, China; yCentre for Eye Research
Australia, Royal Victorian Eye & Ear Hospital, Melbourne, Australia; zSchool
of Computer Science, University of Technology Sydney, Ultimo NSW,
Australia; §Faculty of Medicine, The University of Queensland, Brisbane,
Australia; and {Schwarzman College, Tsinghua University, Beijing, China.
Submitted February 29, 2020; accepted May 18, 2020.
Financial Support: Supported in part by the National Key R&D Program of China
(2018YFC0116500), the Fundamental Research Funds of the State Key
Laboratory in Ophthalmology, National Natural Science Foundation of China
(81420108008), Science and Technology Planning Project of Guangdong
Province (2013B20400003).
The authors report no conflicts of interest.
M.H. holds a patent for using deep learning models to process color fundus images
(patent application number: ZL201510758675.5, patent granted date: May
31,2017)
Address Correspondence and reprint requests to: Mingguang He, MD, PhD, Center
for Eye Research Australia, Royal Victorian Eye & Ear Hospital, University of
Melbourne, Melbourne 3003, Australia. E-mail: mingguang.he@unimelb.edu.au
Copyright  2020 Asia-Pacific Academy of Ophthalmology. Published by Wolters
Kluwer Health, Inc. on behalf of the Asia-Pacific Academy of Ophthalmology.
This is an open access article distributed under the terms of the Creative
Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-
NC-ND), where it is permissible to download and share the work provided it is
properly cited. The work cannot be changed in any way or used commercially
without permission from the journal.
ISSN: 2162-0989
DOI: 10.1097/APO.0000000000000301
 2020 Asia-Pacific Academy of Ophthalmology. https://journals.lww.com/apjoo | 299
PERSPECTIVES
(k¼ 0.63) for the classification of glaucoma based on optic disc
photography. This agreement could be even poorer among general
ophthalmologists (k¼ 0.51) and trainees (k¼ 0.50).6 Similarly,
optometrists achieved sensitivity of 67% and specificity of 84%
with diagnosing diabetic retinopathy (DR), which is below the
recommended screening standard.7
Abràmoff et al8 and Gulshan et al9 published the first 2 articles
on DL technology in the field of ophthalmology, with a task to
detect DR based on retinal fundus photographs in 2016. These 2
studies both reported an area under the curve (AUC) achieving 0.98
to 0.99, a level of accuracy that is far better than any previous
reports based on traditional pattern recognition of lesions. The
power of DL, for the first time, captured the imagination of the
whole field of ophthalmology. Since then, a number of research
groups developed their algorithm based on similar CNNs and
published their results on multiple eye diseases, including
DR,10–14 glaucoma,15–17 age-related macular degeneration
(AMD),18–21 retinopathy of prematurity,22–25 based on a variety
of imaging modalities, including fundus photography, optical
coherence tomography (OCT),26–31 visual field,32–34 and many
others.35,36 Despite this variation, DL algorithm (DLA) applica-
tions primarily focus on 3 major tasks: classification, segmentation,
and prediction using static images collected from medical devices.
The most common DLA application is to generate a global
classification from a specific image, either with or without disease
or on a specific disease severity scale. Some review articles have
been published to summarize the performance of these DLAs with a
variety of diseases,37–42 but several key points must be highlighted.
First, almost all the studies reported robust accuracy,
described as AUC, sensitivity, and specificity, which is far better
than what has been reported in human image graders and machine
learning tools based on traditional pattern recognition algorithms.
For example, in the classification of referrable DR, DLA achieves
an accuracy of AUC 0.98 to 0.99 with a sensitivity of 0.97
(ranging from 0.89 to 0.99) and specificity of 0.96 (ranging from
0.98 to 0.99). These are comparable, if not better than, trained
human graders where unanimous consensus grading by specialist
experts was set as the benchmark.43
Second, almost all the studies used CNNs that are publicly
available. Google Inception V3 is the most commonly used of these,
followed by VGG-net, AlexNet, ResNet, and so on.9,10,13,27,44,45
The adoption of a neural network model often depends on its
availability when the study is conducted. Several studies have used
pretrained CNNs and transfer learning, achieving similar accuracy
with relatively smaller sample sizes.17,26,46–48 In 1 study, 6 CNN
models were simultaneously assessed on AMD classification;
AlexNet yielded a better performance but the difference in perfor-
mance among the networks was minimal.18
Third, CNN image classification is not used only with 2-
dimensional (2-D) images but also with 3-dimensional (3-D)
images such as OCT. A few studies have reported on the perfor-
mance of OCT B-scans where 2-D data were used.27,28,31,49,50
Another recently published study developed and reported on a 3-
D DLA of an OCT image to classify glaucomatous optic neurop-
athy when 3-D parapapillary retinal nerve fiber layer (RNFL) data
were used.51
Fourth, DL is not used only for image classification but also for
lesion detection and image segmentation. This task is more com-
plex than image classification, consisting of creating a boundary
definition around the objects in an image and classifying each of
them. U-net is the most commonly used algorithm for this task, and
it has proved to be accurate in the detection of exudates, hemor-
rhage, and optic discs in fundus photographs. It has also been
accurate with segmenting OCT structures and detecting intraretinal
fluid and subretinal fluid, and OCT pathologies such as neovascu-
larization, macular edema, drusen, geographic atrophy, epiretinal
membrane, vitreous traction, and macular holes.52–56
Fifth, in image classification tasks, DL makes classifications
based on the global image instead of generating a classification
after the detection of a specific lesion. This raises “black box”
concerns where this classification is based on a one-size-fits-all
neural network architecture that is not specific to disease. Heat-
maps have become a popular method to highlight the pixel regions
that contribute most to the DL classification. DL research has
increasingly published their heatmap results where frequently,
heatmap regions do not always necessarily match with the fea-
tures that clinicians commonly used to differentiate disease,
highlighting that the CNN may “see” things differently to
humans.21,27,51,57,58 In fact, some studies have synthesized images
through very small perturbations of the pixels, which can easily
fool the CNN to produce a completely inaccurate output.59,60
Sixth, DL may go beyond simple classification of an image; it
can also predict the prognosis or outcomes of a treatment when
progression data are used as ground truth for training the algorithm.
DL has demonstrated that image data alone, without referring to
other known risk factors, is able to achieve reasonably good
performance in predicting the prognosis for DR, AMD progression,
and structural and functional progression in glaucoma, although
most of these DLAs have yet to be independently validated.19,61–63
Seventh, DL is able to “see” the features that are not
differentiable by humans in certain classification tasks, such as
cardiovascular disease risk factors and smoking status. Poplin et al
from Google demonstrated that a DLA trained with UK Biobank
and US EyePACS datasets was able to classify age, current
smoking status, blood pressure, body mass index, and even 5-
year myocardial infarction with reasonably good accuracy among
independent datasets.64 Their DLA was unexpectedly validated in
a small group of 239 patients selected from a randomly selected
Asian database during the publication peer review process.42 This
finding is intriguing because it was able to prove that the features
of the retina, as a biologically relevant end-organ for the vascular
and neural systems, could be used to classify cardiovascular
disease risks when other known risk factors were not included.
Despite all the fascinating advancements in AI technology,
developments in how to translate and deploy AI technology into
real-world ophthalmology practice remains challenging.
Challenges of AI algorithms in ophthalmology
Challenge #1: Adequate Quantity of Training Data
A useful training dataset should exhaust all possible varia-
tions of disease phenotypes, including but not limited to the
variations of disease severity, ethnicity, artifacts, types of fundus
camera, and confounding of coexisting diseases. In this scenario,
the clinical characteristics of the training set should be clearly
delineated. For instance, an algorithm that was trained based on a
dataset from a screening setting might not be appropriately used in
hospital clinical settings, where disease severity is substantially
different. An algorithm developed based on subjectively defined
glaucoma without referring to the visual field or relevant clinical
diagnostic data may not be appropriate for real-world deployment
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as an end product for glaucoma diagnosis, as the benchmark
used in the training process is different from the purpose
of deployment.
This dependency on large amounts of data for accurate
algorithm development has become an impediment to the adop-
tion of AI in clinical practice. Hospitals may have a large amount
of data but not have good access to computer science and AI
experts. The data in hospitals are often not well organized for
meaningful data mining, and other obstacles such as regulation
considerations, privacy protection, ethical issues, and legal con-
cerns may further hinder data sharing. Similarly, computer sci-
ence companies have the computing power and AI expertise, but
they do not have access to clinical datasets. Although the “Big
Nine” (Google, Alibaba, Amazon, Tencent, Apple, Baidu, Face-
book, IBM, and Microsoft) have invested tremendous amounts of
resources on AI development, that does not mean they had
sufficient access to clinical data. It would be tremendously helpful
to create freely available disease or device-specific shared data
resources for computer experts to use in testing different algo-
rithm designs. The publicly available ImageNet dataset that has
been used to generate many breakthroughs in image recognition;
the public datasets for DR, organized by Kaggle, which has been
used by many developers for DR algorithms; the UK Biobank’s
open-source data for eye disease classification and prediction
model development are good examples of successful data sharing.
Nevertheless, alternative learning methods have recently been
proposed that can simulate how the human brain works and learn
from fewer examples. Using generative adversarial networks, one
group of researchers65–68 created or synthesized a large number of
diverse and random computed tomography and magnetic reso-
nance imaging images from scratch and claimed that the set of
images could be used as a training set for future CNN develop-
ment. These efforts however remain yet to be proven and have not
achieved great success to date.69
Challenge #2: Appropriate Definition of Ground
Truth and Labeling
A majority of algorithms are developed based on images
retrieved directly from medical devices, and then a number of
experts are asked to subjectively grade (or label) these images.
The ground truth is determined by the unanimity of the graders
along a continuum, such as normal, probably normal, indetermi-
nate, probably abnormal, or definitely abnormal; or by simply
classifying the images into normal or abnormal. This approach is
often subject to significant misclassification, errors, and insuffi-
ciency because expert classification is subjective, and there is
significant interobserver variation.70,71 The label from subjective
classification does not necessarily contain clinically important
information such as the likelihood of progression, potential treat-
ments, responses to treatment, and so on. An ideal ground truth
should be based on criterion standard definitions and retrieved
from real-world clinical data such as pathology reports and
electronic medical records, which often depend on multiple
modalities of imaging devices and clinical procedure details that
comply with diagnostic standards.
Challenge #3: Assessment of the Accuracy of AI
Algorithms
Critical assessment of the accuracy of an AI algorithm should
be based on widely recognized principles of evidence-based
medicine, just like other new medicines or devices. An article
in preprint that is released via online repositories, for instance,
arXiv.org; peer-reviewed articles describing technical develop-
ments published in computer science journals; or even peer-
reviewed articles reporting diagnostic performance in clinical
journals do not necessarily fully establish the accuracy of tech-
nologies or justify the adoption of the technology in real-world
clinical practice. In this context, an AI algorithm developed for
diagnosis or classification should comply with the Standards for
Reporting Diagnostic Accuracy (STARD) statement, and an AI
algorithm developed for prediction should follow the Transparent
Reporting of a Multivariate Prediction Model for Individual
Prognosis or Diagnosis (TRIPOD) statement for transparent
reporting of study settings, study population, definitions and
measurements of outcomes, time, and interval of follow-up,
and so on, as AI algorithms are sensitive to the target population,
equipment used, imaging protocols, and referral standards.72,73 A
number of initiatives to develop specific guidelines for AI-based
clinical trials are currently under deliberation.74–76 These include
the Consolidated Standards of Reporting Trial (CONSORT)-AI,
Specific Protocol Items: Recommendations for Interventional
Trials (SPIRIT)-AI and TRIPOD-ML statements, which are
extensions of existing guidelines that provide clinical trial proto-
col and reporting standards.
Overfitting is the most common bias in AI algorithm devel-
opment, where the algorithm is overfitted to the training set. This
can be driven by a mistake in training set development, for
instance, using one type of fundus camera to collect images
for the disease and another type of fundus camera for the normal
group, so that the algorithm essentially ends up classifying the
type of fundus camera instead of disease and nondisease. Reliable
external validation of the data collected in newly recruited
patients or at different sites, or using different models of device
as an independent study, is the best way to mitigate overfitting
problems. There are, in general, 2 approaches to external valida-
tion of algorithms noted in published studies—either a publicly
available image dataset or a prospective study. In ophthalmology,
Abràmoff et al,8 Gargeya and Leng,58 and Gulshan et al9 used the
Messidor-2 dataset, E-Ophtha databases, or EyePACS-1 as a
reference for external validation. However, an ideal validation
should be based on images that have never been used in the
training set, and a validation process conducted by researchers is
often not able to ensure this is the case. Therefore, an ideal
validation for an image dataset should be done on larger stan-
dardized datasets provided by an independent party using a setup
similar to Kaggle’s public image recognition challenges, where
the ground truth has not been disclosed, so that a neutral objective
benchmark can be established.
Similar to the assessment of other new medicines or devices,
the assessment of AI algorithms should ideally be carried out in a
prospective clinical trial. Recently, Lin et al77 conducted a clinical
trial to compare an AI-assisted cataract classification technique
versus ophthalmologists in real-world settings, and found the AI
technique was less accurate in diagnosing childhood cataracts
than ophthalmologists but was more efficient. There have been 25
items registered under eye diseases on the clinical trials website
(https://clinicaltrials.gov/) using terms such as “convolutional
neural network,” or “deep learning,” or “machine learning,” or
“artificial intelligence,” and “ophthalmology,” with most focused
on DR, glaucoma, cataracts, visual acuity assessment, and so on.
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Challenge 4: Mode of Care of AI Adoption
Currently available AI algorithms in ophthalmology funda-
mentally enable tasks of classification, detection, or segmenta-
tion. Classification refers to assigning an entire image or lesion in
a particular image to a category, for example, the DR severity
scale. Detection is done to identify a specific abnormality within
an image, for example, choroidal neovascular lesions in an OCT
image. Segmentation is done to identify or isolate a specific
structure of interest in an image, such as isolating the RNFL in
an OCT image.
The outcomes of interest in AI classification can be multiple
and varied. The most common outcome of interest is separating
abnormal from normal patients. This perhaps appears to be a very
simple day-to-day task for ophthalmologists, but it could be
challenging for noneye professionals, such as asking an endocri-
nologist to classify an image as either with or without referable
DR, despite this possibly being part of their professional training
for the management of diabetic complications. The second com-
mon outcome of interest is to classify or assign the images into
severity categories or grading schemes, such as classifying an
image on the DR severity scale. This classification task is often
more difficult and less accurate than a dichotomous classification
because an effective differentiation between certain grades could
be challenging when the difference is minimal, for instance,
differentiating normal and mild DR where the only difference
is the presence of a microaneurysm. The third outcome of interest
is to predict the prognosis of a disease, such as to differentiate
progressive glaucoma from stable ones.
Challenge #5: Integrate AI Into Clinical Pathways
Bossuyt et al78 proposed 3 clinical pathways (triage, replace-
ment, and add-on) to integrate new diagnostic tests into existing
clinical pathways that would be appropriate for AI deployment.
In the triage model, AI algorithms can be used as a triage tool
for opportunistic screening in noneye clinical settings or as a tool
for assisting integration into pathways of grading in reading
centers. In Australia, our research team has installed an AI system
in endocrinology and primary care settings to enable opportunistic
screening and targeted referral so that DR patients are referred to
eye professionals (Fig. 1), whereas the normal ones stay for
routine glucose management. In this research deployment model,
the AI system was used to generate a report that would be
reviewed by a qualified physician such as an endocrinologist
who would sign off on the diagnosis. In this case, the AI is
considered a decision support tool for diagnosis. In China, our
research team works with a local software company to provide
technical support for a nationwide DR screening program where
the AI is used as the first triage tool for identifying “super-normal”
cases, defined as classifications of normal and gradable in all 4
images collected for an individual (Fig. 2). In the case of super-
normal, a report from AI is generated and sent to the patient at
their point-of-care. A pilot study proved that this model could
reduce the workload for telemedicine grading centers by >50%.
In a replacement model, the AI algorithm is used to replace
the clinical diagnosis task of a clinician because the AI can be
more accurate, rapid, and reproducible and less dependent on
access to a clinician. This model of care is feasible only for tasks
where AI is definitively superior to physicians (such as estimation
of bone age in radiology) or for tasks that are simple enough to
carry out, such as classifying the image as that of a right eye or left
eye, but often require strict regulatory approval.
An add-on model of care refers to where AI is used as a
procedure that is used in parallel with or after diagnosis from
clinicians. This model is often used when the task involves time-
consuming and repetitive work, such as counting lesions (eg,
microaneurysms in DR grading) or automatically measuring
RNFL thickness that involve lots of manual segmentation on a
large number of OCT B-scans (Fig. 3).
Challenge #6: AI Clinical Adoption Is Beyond
Clinical Consideration
Successful AI deployment in clinical practice requires the active
involvement of all stakeholders, including patients, ophthalmolo-
gists, imaging technicians, hospital administrations, regulatory
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bodies, and industry. It is important to ensure that all stakeholders will
benefit from AI deployment and are willing to collaboratively
facilitate the development of best practices by integrating ethics,
patient consent, privacy protection, data ownership and sharing,
integration with existing electronicmedical system, and user-friendly
software interface for targeted clinical settings.
In 2016, the 21st Century Cures Act was signed into law,
aiming to accelerate the discovery, development, and delivery of
new cures and treatments. The US Food and Drug Administra-
tion’s (FDA’s) current strategic policy emphasizes leveraging
innovation, including digital health technologies, and is
highlighted by new software as a medical device (SaMD) and
digital health regulatory approval pathways for AI and computer
vision algorithms.79,80 To date, the FDA has approved several AI-
based SaMDs, including the IDx ML-based software system for
automated detection of DR and an AI product for use with
computed tomography scans for indicators associated with
stroke.81,82 Most of these approvals are for algorithms that are
locked in before going to market, but the FDA is currently also
considering SaMD regulatory frameworks for continuous learning
and adaptive algorithms that are potentially able to be adapted to
improve performance in real time.
Challenge #7: Security Issues in AI Deployment
Recently, various attack methods have proved effective
against existing DL models. For example, some studies found that
by adding adversarial noises to a raw image, a well-trained model
could be successfully fooled into making a wrong decision that is
totally opposite to the ground truth.83 The adversarial noise can be
carefully designed to ensure the manipulated image is visually the
same as the raw image such that it is almost impossible for humans
to detect. Worse, this kind of adversarial attack can be conducted as
a black box attack, meaning that no previous knowledge of the
model details, such as information about the model’s structure or
parameters, is required by an attacker.
The vulnerability of DL models has spurred the community
to seriously rethink the security and robustness of AI in real-world
deployments, especially in the medical domain.84 Scaling up AI
systems for clinical use without any defendable countermeasures
means that any falsified diagnosis could lead to considerable risks.
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FIGURE 2. Artificial intelligence is used as an initial triage strategy to maximize efficiency of manual grading. AI indicates artificial intelligence.
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Case Study: IDx-DR and Real-World Challenges of
DLA
The limitations of retrospective in silico validation of DLA
are significant. Real-world prospective trials are now increasingly
essential for clinical uptake and regulatory approval of DLA
systems. In a landmark study by Abràmoff et al,12 the efficacy
of the “IDx-DR” system, a fully autonomous screening system for
more-than-mild DR (mtmDR), was evaluated in a real-world
prospective trial of 900 patients across 10 primary care sites in
the United States.
This trial is notable as it both addresses and reflects many of
the key challenges described in this article. The DLA was
assessed in a prospective clinical trial, where inclusion criteria
and the clinical setting were strictly defined. Eligible participants
were asymptomatic patients, diagnosed with diabetes and not
previously diagnosed with DR, in a primary care setting. All
images were captured with 1 retinal camera model, the Topcon
NW400 system. Captured images were evaluated by 2 IDx-DR
image quality and diagnostic algorithms, which determined the
presence of mtm DR. Results produced by the DLA were com-
pared with high-quality ground-truth Wisconsin Fundus Photo-
graph Reading Center widefield stereoscopic photography
and OCT.
The system achieved a sensitivity and specificity of 87.2%
and 90.7%, respectively, meeting endpoints predetermined by the
US FDA. This allowed it to achieve the first regulatory approval
ever for an autonomous AI-based diagnostic system.85 Following
this precedent, prospective real-world validation trials are now
essential for future regulatory approval of DLA systems. Notably,
however, regulatory approval for the IDx-DR system remains
limited to the cohort that was defined in the system’s validation
trial. This includes the detection of mtmDR only in adults
diagnosed with diabetes who have not been previously diagnosed
with DR, and in nondilated images captured by the Topcon
NW400 camera.86
The real-world validation of DLA systems in less-controlled
real-world settings remains immature. In the first human-centered
observational study of a DLA in clinical care published in
April 2020, Google Health researchers working in 11 clinics
across Thailand encountered a number of socioenvironmental
factors that limited the accuracy and adoption of a DR screening
DL system.87 Challenges include clinic screening conditions,
image gradeability affecting system performance, internet speed
and connectivity, and the impact of referrals on patient time. For
instance, several clinics reported issues with image gradeability as
fundus images were captured in nondarkened clinics that resulted
in insufficient pupil dilation and insufficient quality images.
Alternative darkened clinic rooms could not be found. Images
were often rejected for grading by the DLA, requiring multiple
attempts that added frustration and work to an already busy clinic.
Furthermore, the DLA system required images to be uploaded to
the cloud for assessment. The study sites often experienced slower
and less reliable connections that slowed down the overall
screening workflow, and reduced the number of patients a clinic
could screen daily. Lastly, a large number of patients were
discouraged from participation in the study, after understanding
during the consent process that a positive screening result would
require further assessment in a hospital an hour drive away, opting
out to avoid possible additional time burden.
Thus, as described in this article, successful AI deployment
in clinical practice requires the involvement of all stakeholders,
including patients, ophthalmologists, imaging technicians, hospi-
tal administrations, regulatory bodies, and industry. End-users
and their environment determine implementation, which may be
as important as the accuracy of the algorithm itself. Early and
material consideration of these real-world factors will be essential
to the successful future clinical deployment of DLA systems.
THE FUTURE
There have been arguments made and concerns expressed
that AI will replace professionals in future practice. However, one
should note that currently, supervised ML is typically trained to
discriminate features based on a trusted training set for only a
limited assigned task, whereas humans are able to transfer expe-
rience and expertise to a new task through reasoning. A DLA
system may be able to classify the presence and severity of a
limited number of predefined diseases, to segment image struc-
tures, or even predict disease prognosis more accurately and
perhaps more efficiently than humans. However, it is unable to
make a valid diagnosis of diseases that it has not been trained for,
nor able to accurately perform clinical reasoning based on multi-
modality data and experience, interact with patients properly, and
perform treatment procedures like human doctors. To paraphrase
the prominent AI expert Ng, the measure of a good AI technology
is that it does well what humans can do, but easier and quicker, in
1 second.88 This will likely remain true until the development of
the “singularity”: a hypothetical future point in time when
“general AI” becomes available such that machines can learn,
reason, and create like humans, undoubtedly and unforeseeably
changing human civilization.
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